Home  »  Markets   »  X4 Pharmaceuticals Inc. (XFOR) Review – Maki...

X4 Pharmaceuticals Inc. (XFOR) Review – Making Smarter Decisions

X4 Pharmaceuticals Inc. (NASDAQ: XFOR) is -8.80% lower on its value in year-to-date trading and has touched a low of $0.65 and a high of $2.41 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The XFOR stock was last observed hovering at around $0.92 in the last trading session, with the day’s loss setting it -0.01% off its average median price target of $4.50 for the next 12 months. It is also 87.0% off the consensus price target high of $7.00 offered by 8 analysts, but current levels are 69.67% higher than the price target low of $3.00 for the same period.

Currently trading at $0.91, the stock is -4.34% and -10.11% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.63 million and changing -1.64% at the moment leaves the stock -27.48% off its SMA200. XFOR registered -49.69% loss for a year compared to 6-month loss of -19.14%.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


The stock witnessed a -4.16% gain in the last 1 month and extending the period to 3 months gives it a 0.62%, and is -7.55% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.71% over the week and 7.68% over the month.

Distance from 52-week low is 39.32% and -62.46% from its 52-week high.

X4 Pharmaceuticals Inc. (XFOR) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for X4 Pharmaceuticals Inc. (XFOR) is a “Buy”. 8 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

The EPS is expected to shrink by -28.80% this year

X4 Pharmaceuticals Inc. (XFOR) Top Institutional Holders

The shares outstanding are 83.21M, and float is at 68.54M with Short Float at 1.85%.

X4 Pharmaceuticals Inc. (XFOR) Insider Activity

The most recent transaction is an insider sale by Mostafa Adam S., the company’s Chief Financial Officer. SEC filings show that Mostafa Adam S. sold 52,500 shares of the company’s common stock on Mar 10 at a price of $0.84 per share for a total of $44100.0. Following the sale, the insider now owns 93696.0 shares.

X4 Pharmaceuticals Inc. disclosed in a document filed with the SEC on Mar 10 that Ragan Paula (President and CEO) sold a total of 49,678 shares of the company’s common stock. The trade occurred on Mar 10 and was made at $0.84 per share for $41730.0. Following the transaction, the insider now directly holds 0.56 million shares of the XFOR stock.

Still, SEC filings show that on Mar 10, DiBiase Mary (Chief Operating Officer) disposed off 18,192 shares at an average price of $0.84 for $15281.0. The insider now directly holds 152,714 shares of X4 Pharmaceuticals Inc. (XFOR).

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts